14-CpG-Based Signature Improves the Prognosis Prediction of Hepatocellular Carcinoma Patients

Table 5

Univariate analysis and multivariate analysis of clinicopathologic data and the MSH with OS in the validation cohort.

Variables	Univariate analysis			Multivariate analysis
	Hazard ratio	95% CI	value	Hazard ratio	95% CI	value
Gender (male vs female)	1.155	0.595–2.242	0.671
Age (>60 vs <60 years)	1.165	0.619–2.191	0.636
BMI (>25 vs <25)	0.834	0.419–1.661	0.606
AFP (>25 vs <25)	1.576	0.712–3.486	0.262
Cirrhosis (yes vs no)	0.561	0.202–1.559	0.267
Child-Pugh stage (B vs A)	1.396	0.179–10.882	0.75
Adjacent tissue inflammation (yes vs no)	1.239	0.520–2.953	0.628
Tumor histologic grade (G3+G4 vs G1+G2)	1.115	0.576–2.159	0.747
Surgical margin status (R1 vs R0)	1.714	0.523–5.609	0.373
AJCC TNM stage (III + IV vs I + II)	5.709	2.906–11.217	0.000	8.884	2.533–31.16	0.001
MSH (high risk vs low risk)	1.979	1.019–3.864	0.044	3.379	1.054–10.834	0.041

MSH: methylation signature for HCC.